BAH243
/ Essen Biotech
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
August 09, 2024
Investigation Into the Use of BAH243 Lentiviral Vector for Gene Therapy in Treating Sickle Cell Disease
(clinicaltrials.gov)
- P1/2 | N=85 | Recruiting | Sponsor: Essen Biotech | Not yet recruiting ➔ Recruiting | Initiation date: Nov 2024 ➔ Aug 2024
Enrollment open • Gene therapy • Trial initiation date • Viral vector • Gene Therapies • Genetic Disorders • Hematological Disorders • Sickle Cell Disease
May 03, 2024
Investigation Into the Use of BAH243 Lentiviral Vector for Gene Therapy in Treating Sickle Cell Disease
(clinicaltrials.gov)
- P1/2 | N=85 | Not yet recruiting | Sponsor: Essen Biotech
Gene therapy • New P1/2 trial • Viral vector • Gene Therapies • Genetic Disorders • Hematological Disorders • Sickle Cell Disease
1 to 2
Of
2
Go to page
1